Breaking News
Dermata Therapeutics, Inc. DRMAW has experienced a notable surge in after-hours trading following the company’s announcement of a newly issued patent in Japan for its DMT410 program, which targets the treatment of hyperhidrosis.
Key Developments
The issuance of the patent, the first for DMT410, comes as a significant milestone for Dermata.
The program’s use of the company’s innovative Spongilla technology for the topical delivery of botulinum toxin in hyperhidrosis treatment has generated substantial interest, with discussions of potential partnership opportunities to further advance DMT410.
Expressing confidence in the program, Gerry Proehl, Dermata’s chairman, president, and CEO, stated, “We believe this patent issuance further validates DMT410’s novel concept to easily deliver botulinum toxin topically instead of requiring patients to receive multiple injections.”
Proehl added, “We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis which has no currently approved products.”
Market Response
DRMA Price Action: Shares of Dermata surged by 96.7% to $1.20 in the after-hours session at the time of publication, as reported by Benzinga Pro.
Photo: Steve Buissinne from Pixabay